Results 11 to 20 of about 20,805 (196)

HIV-gp140-Specific Antibodies Generated From Indian Long-Term Non-Progressors Mediate Potent ADCC Activity and Effectively Lyse Reactivated HIV Reservoir

Frontiers in Immunology, 2022
Strategies to reduce the human immunodeficiency virus (HIV) reservoir are urgently required. The antibody-dependent cellular cytotoxicity (ADCC)-mediating anti-HIV antibodies have shown an association with HIV control.
Jayshree R. Dhande, Rajani D. Bagul, Madhuri R. Thakar   +2 more
doaj   +1 more source

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis

Cell Reports, 2018
Summary: Destruction of cancer cells by therapeutic antibodies occurs, at least in part, through antibody-dependent cellular cytotoxicity (ADCC), and this can be mediated by various Fc-receptor-expressing immune cells, including neutrophils. However, the
Hanke L. Matlung, Liane Babes, Xi Wen Zhao, Michel van Houdt, Louise W. Treffers, Dieke J. van Rees, Katka Franke, Karin Schornagel, Paul Verkuijlen, Hans Janssen, Pasi Halonen, Cor Lieftink, Roderick L. Beijersbergen, Jeanette H.W. Leusen, Jaap J. Boelens, Ingrid Kuhnle, Jutte van der Werff Ten Bosch, Karl Seeger, Sergio Rutella, Daria Pagliara, Takashi Matozaki, Eiji Suzuki, Catharina Willemien Menke-van der Houven van Oordt, Robin van Bruggen, Dirk Roos, Rene A.W. van Lier, Taco W. Kuijpers, Paul Kubes, Timo K. van den Berg   +28 more
doaj   +1 more source

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody

Frontiers in Immunology, 2022
Targeting CD19 represents a promising strategy for the therapy of B-cell malignancies. Although non-engineered CD19 antibodies are poorly effective in mediating complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC)
Carina Lynn Gehlert, Pegah Rahmati, Ammelie Svea Boje, Dorothee Winterberg, Steffen Krohn, Thomas Theocharis, Elisa Cappuzzello, Anja Lux, Falk Nimmerjahn, Ralf J. Ludwig, Marta Lustig, Thies Rösner, Thomas Valerius, Denis Martin Schewe, Christian Kellner, Katja Klausz, Matthias Peipp   +16 more
doaj   +1 more source

Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines

BMC Cancer, 2012
Background Despite strong efforts to improve clinical outcome of ovarian cancer patients by conventional and targeted immuno-based therapies, the prognosis of advanced ovarian cancer is still poor.
Gottschalk Nina, Lang Stephan, Kimmig Rainer, Singh Mahavir, Brandau Sven   +4 more
doaj   +1 more source

Development of a Macrophage-Based ADCC Assay

Vaccines, 2021
Fc-dependent effector functions are an important determinant of the in vivo potency of therapeutic antibodies. Effector function is determined by the combination of FcRs bound by the antibody and the cell expressing the relevant FcRs, leading to antibody-
Melissa B. Uccellini, Sadaf Aslam, Sean T. H. Liu, Fahmida Alam, Adolfo García-Sastre   +4 more
doaj   +1 more source

Applicability of Traditional In Vitro Toxicity Tests for Assessing Adverse Effects of Monoclonal Antibodies: A Case Study of Rituximab and Trastuzumab

Antibodies, 2018
Monoclonal antibody (mAb) therapeutics have a promising outlook within the pharmaceutical industry having made positive strides in both research and development as well as commercialisation, however this development has been hampered by manufacturing ...
Arathi Kizhedath, Simon Wilkinson, Jarka Glassey   +2 more
doaj   +1 more source

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Cells, 2020
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a ...
Ilaria Saltarella, Vanessa Desantis, Assunta Melaccio, Antonio Giovanni Solimando, Aurelia Lamanuzzi, Roberto Ria, Clelia Tiziana Storlazzi, Maria Addolorata Mariggiò, Angelo Vacca, Maria Antonia Frassanito   +9 more
doaj   +1 more source

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma

Frontiers in Oncology, 2021
Monoclonal antibodies (mAbs) directed against antigen-specific of multiple myeloma (MM) cells have Fc-dependent immune effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody ...
Alessandra Romano, Paola Storti, Valentina Marchica, Grazia Scandura, Laura Notarfranchi, Luisa Craviotto, Luisa Craviotto, Francesco Di Raimondo, Francesco Di Raimondo, Nicola Giuliani   +9 more
doaj   +1 more source

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Journal of Hematology & Oncology, 2016
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Larysa Sanchez, Yucai Wang, David S. Siegel, Michael L. Wang   +3 more
doaj   +1 more source

Increased monocyte-mediated antibody-dependent cellular cytotoxicity (ADCC) in Hodgkin's disease [PDF]

British Journal of Cancer, 1980
Monocyte-mediated antibody-dependent cellular cytotoxicity (ADCC) was tested in 23 patients with histologically proven Hodgkin's disease and 29 healthy normal controls. Seven patients presented with active and 16 with inactive disease. The lytic capacity of the individual monocytes was significantly (P < 0.02) higher in patients with Hodgkin's disease ...
H, Pehamberger, H, Ludwig, P, Pötzi, W, Knapp   +3 more
openaire   +2 more sources